Molecular Subtype
Triple-Negative Breast Carcinoma
CI-CAN-00008567TNBCExplore in graph →
417 active trials3 approved drugs8 evidence items
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00008567TNBCExplore in graph →
Clinical trials
950 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (168)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07108309 | BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer(AREAL) | recruiting | Phase 2 | 124 | BiocadINDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT07104266 | Triple Negative Breast Cancer and Celecoxib. Pilot Study | recruiting | Phase 2 | 30 | Université de SherbrookeOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT03729596 |
| MGC018 With or Without MGA012 in Advanced Solid Tumors |
| terminated |
| Phase 1 / Phase 2 |
| 143 |
| MacroGenicsINDUSTRY |
| 4 |
| Jul 31, 2025 |
| clinicaltrials |
| NCT05435352 | Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment(PEAR-TNBC) | terminated | — | 34 | Ourotech, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07007780 | Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC | not yet recruiting | Phase 2 | 35 | Xijing HospitalOTHER | 0 | Jul 29, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT03654547 | Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer | completed | Phase 1 | 48 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 2 | Jul 24, 2025 | clinicaltrials |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 11 | Numab Therapeutics AGINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05300958 | Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05632848 | Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients | completed | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Jul 21, 2025 | clinicaltrials |
| NCT06355024 | Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer | completed | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07073755 | Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd | recruiting | — | 200 | Hunan Cancer HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT06246786 | Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer) | withdrawn | Early Phase 1 | 0 | Virginia G. KaklamaniOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT04313075 | A Compassionate Use Study of Leronlimab in Breast Cancer | no longer available | — | — | CytoDyn, Inc.INDUSTRY | 0 | Jul 15, 2025 | clinicaltrials |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | HutchmedINDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT04083963 | Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer | active not recruiting | Phase 2 | 13 | University of Illinois at ChicagoOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT05722795 | Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)(I-CONIC) | recruiting | N/A | 40 | Vastra Gotaland RegionOTHER_GOV | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06590558 | Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 3, 2025 | clinicaltrials |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | terminated | Phase 1 | 57 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT05891197 | A Biomarker Screening Protocol for Participants With Solid Tumors(START) | terminated | — | 10 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT07046195 | Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer | active not recruiting | — | 250 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03106415 | Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 23 | Mayo ClinicOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06769425 | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors(HS-10502) | recruiting | Phase 1 | 157 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT05086731 | Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer | completed | N/A | 33 | Emory UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | completed | Phase 1 | 185 | Novartis PharmaceuticalsINDUSTRY | 7 | Jun 13, 2025 | clinicaltrials |
| NCT07021261 | Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients | not yet recruiting | Phase 3 | 440 | Fudan UniversityOTHER | 0 | Jun 13, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT07018427 | Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer | active not recruiting | — | 70 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | terminated | Phase 1 / Phase 2 | 49 | Formation BiologicsINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06067061 | "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer(neoBREASTIM) | terminated | Phase 1 / Phase 2 | 2 | Institut CurieOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07011823 | Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC(KEY-MELT) | not yet recruiting | Phase 2 | 20 | Gangnam Severance HospitalOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT07005583 | Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer | not yet recruiting | Phase 2 | 46 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | terminated | Phase 1 | 221 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT04849364 | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer(PERSEVERE) | terminated | Phase 2 | 52 | Bryan Schneider, MDOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06991790 | Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration | recruiting | — | 51 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | Numab Therapeutics AGINDUSTRY | 3 | May 23, 2025 | clinicaltrials |
| NCT06975644 | Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC) | not yet recruiting | N/A | 55 | Zhejiang Provincial People's HospitalOTHER | 0 | May 22, 2025 | clinicaltrials |
| NCT06367088 | Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer | recruiting | Phase 2 | 27 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT03742349 | Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | terminated | Phase 1 | 64 | Novartis PharmaceuticalsINDUSTRY | 9 | May 18, 2025 | clinicaltrials |
| NCT06977542 | Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer | not yet recruiting | Phase 2 | 53 | Fudan UniversityOTHER | 0 | May 18, 2025 | clinicaltrials |
| NCT06965361 | Stromal Tumor-Infiltrating Lymphocyte Levels Are Associated With Immune Checkpoint Proteins In Triple Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy(TIL; PD1; PDL1) | completed | — | 54 | Ziauddin UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06976021 | Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy(INTROSPECTION) | not yet recruiting | Phase 2 | 60 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 0 | May 16, 2025 | clinicaltrials |
| NCT04947189 | Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer(4CAST) | recruiting | Phase 1 / Phase 2 | 65 | St Vincent's Hospital, SydneyOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03562637 | Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC | active not recruiting | Phase 3 | 575 | OBI Pharma, IncINDUSTRY | 13 | May 9, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT06955156 | Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC | unknown | Phase 2 | 50 | QIAO LIOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT01818063 | Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer | completed | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 7, 2025source: clinicaltrials